iTeos Therapeutics, Inc. (ITOS) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	10-K	S-1
Revenues	267.6	344.8	0.0	0.0	0.0
Revenue growth	-22.4%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0
Gross profit	267.6	344.8	0.0	0.0	0.0
Gross margin	100.0%	100.0%
Selling, general and administrative [+]	141.3	99.9	45.2	8.8	4.3
General and administrative				8.8	4.3
Research and development				19.2	17.2
Other operating expenses			-45.2	-1.0
EBITDA [+]	127.1	245.5	0.5	-26.4	-21.0
EBITDA growth	-48.2%	45788.6%	-102.0%	25.8%
EBITDA margin	47.5%	71.2%
Depreciation and amortization	0.8	0.6	0.5	0.6	0.5
EBIT [+]	126.3	244.9	0.0	-27.0	-21.5
EBIT growth	-48.4%		-100.0%	25.7%
EBIT margin	47.2%	71.0%
Non-recurring items				1.0
Interest income, net [+]	11.4	0.1			-0.1
Interest expense					0.1
Interest income	11.4	0.1
Other income (expense), net	11.1	11.5	-38.1	5.7	3.5
Pre-tax income	148.7	256.5	-38.1	-22.3	-18.0
Income taxes	52.1	41.9	-0.1	0.1	0.0
Tax rate	35.0%	16.4%	0.1%
Net income	96.7	214.5	-38.0	-26.5	-18.1
Net margin	36.1%	62.2%

Basic EPS [+]	$2.72	$6.10	($2.88)	($130.85)	($29.36)
Growth	-55.4%	-311.9%	-97.8%	345.7%
Diluted EPS [+]	$2.56	$5.68	($2.88)	($130.85)	($29.36)
Growth	-54.9%	-297.3%	-97.8%	345.7%

Shares outstanding (basic) [+]	35.6	35.2	15.1	0.2	0.6
Growth	1.1%	133.3%	7336.3%	-67.0%
Shares outstanding (diluted) [+]	37.8	37.8	15.1	0.2	0.6
Growth	0.0%	150.5%	7336.3%	-67.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.